Abstract
Background Exposure to PM2.5 arising from solid fuel combustion is estimated to result in approximately 2.3 million premature deaths and 90 million lost disability-adjusted life years annually. ‘Clean’ cooking interventions attempting to mitigate this burden have had limited success in reducing exposures to levels that may yield improved health outcomes.
Objectives This paper reports exposure reductions achieved by a liquified petroleum gas (LPG) stove and fuel intervention for pregnant mothers in the Household Air Pollution Intervention Network (HAPIN) randomized controlled trial.
Methods The HAPIN trial included 3,195 households primarily using biomass for cooking in Guatemala, India, Peru, and Rwanda. 24-hour exposures to PM2.5, carbon monoxide (CO), and black carbon (BC) were measured for pregnant women once before randomization into control (n=1605) and LPG arms (n=1590) and twice thereafter (aligned with trimester). Changes in exposure were estimated by directly comparing exposures between intervention and control arms and by using linear mixed-effect models to estimate the impact of the intervention on exposure levels.
Results Median exposures of PM2.5, BC, and CO post-randomization in the intervention arm were lower by 66% (70.7 versus 24.0 μg/m3), 71% (9.6 versus 2.8 μg/m3), and 83% (1.2 versus ppm), respectively, compared to the control arm. Exposure reductions were similar across research locations. Post-intervention PM2.5 exposures in the intervention arm were at the lower end of what has been reported for LPG and other clean fuel interventions, with 69% of PM2.5 samples falling below the WHO Annual Interim Target 1 of 35 μg/m3.
Discussion This study indicates that an LPG intervention with high displacement of traditional cooking can reduce exposures to levels thought to be associated with health benefits. Success in reducing exposures was likely due to strong performance of, and high adherence to the intervention.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02944682
Funding Statement
This study was funded by the U.S. National Institutes of Health [cooperative agreement 1UM1HL134590] in collaboration with the Bill & Melinda Gates Foundation [OPP1131279]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. A multidisciplinary, independent Data and Safety Monitoring Board (DSMB) appointed by the National Heart, Lung, and Blood Institute (NHLBI) monitors the quality of the data and protects the safety of patients enrolled in the HAPIN trial. NHLBI DSMB: Nancy R Cook, Stephen Hecht, Catherine Karr (Chair), Joseph Millum, Nalini Sathiakumar, Paul K Whelton, Gail G Weinmann (Executive Secretary). Program Coordination: Gail Rodgers, Bill & Melinda Gates Foundation; Claudia L Thompson, National Institute of Environmental Health Science; Mark J. Parascandola, National Cancer Institute; Marion Koso-Thomas, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Joshua P Rosenthal, Fogarty International Center; Conception R Nierras, NIH Office of Strategic Coordination Common Fund; Katherine Kavounis, Dong- Yun Kim, Antonello Punturieri, and Barry S Schmetter, NHLBI. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US National Institutes of Health or Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. National Institutes of Health or Department of Health and Human Services or the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol has been reviewed and approved by institutional review boards (IRBs) or Ethics Committees at Emory University (00089799), Johns Hopkins University (00007403), Sri Ramachandra Institute of Higher Education and Research (IEC-N1/16/JUL/54/49) and the Indian Council of Medical Research - Health Ministry Screening Committee (5/8/4-30/(Env)/Indo-US/2016-NCD-I), Universidad del Valle de Guatemala (146-08-2016) and Guatemalan Ministry of Health National Ethics Committee (11-2016), Asociacion Benefica PRISMA (CE2981.17), the London School of Hygiene and Tropical Medicine (11664-5) and the Rwandan National Ethics Committee (No.357/RNEC/2018), and Washington University in St. Louis (201611159). The study has been registered with ClinicalTrials.gov (Identifier NCT02944682).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement: Michael Johnson and Ricardo Piedrahita work for Berkeley Air Monitoring Group, a private consulting firm. Berkeley Air provides monitoring and evaluation services for the household energy sector. Berkeley Air is independent and does not promote any particular technology or fuel. The other authors declare they have no actual or potential competing financial interests.
(co-first)
Data Availability
All data produced in the present study are available upon reasonable request to the authors after completion of the trial.
